Orchard Therapeutics ORTX Stock
Orchard Therapeutics Price Chart
Orchard Therapeutics ORTX Financial and Trading Overview
| Orchard Therapeutics stock price | 16.7 USD |
| Previous Close | 4.95 USD |
| Open | 5 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1100 |
| Day's Range | 4.91 - 5.09 USD |
| 52 Week Range | 3.6 - 7.2 USD |
| Volume | 24.16K USD |
| Avg. Volume | 58.31K USD |
| Market Cap | 90.47M USD |
| Beta (5Y Monthly) | 0.902866 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.75 USD |
ORTX Valuation Measures
| Enterprise Value | -1836225 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.2955145 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.9255037 |
| Price/Book (mrq) | 0.8899764 |
| Enterprise Value/Revenue | -0.1 |
| Enterprise Value/EBITDA | 0.016 |
Trading Information
Orchard Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.902866 |
| 52-Week Change | -15.34% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.2 USD |
| 52 Week Low | 3.6 USD |
| 50-Day Moving Average | 5.08 USD |
| 200-Day Moving Average | 4.98 USD |
ORTX Share Statistics
| Avg. Volume (3 month) | 58.31K USD |
| Avg. Daily Volume (10-Days) | 27.88K USD |
| Shares Outstanding | 18.43M |
| Float | 10.9M |
| Short Ratio | 1.28 |
| % Held by Insiders | 5.40% |
| % Held by Institutions | 34.64% |
| Shares Short | 88.48K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.47% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -634.070% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.62% |
| Return on Equity (ttm) | -89.27% |
Income Statement
| Revenue (ttm) | 18.37M USD |
| Revenue Per Share (ttm) | 1.4 USD |
| Quarterly Revenue Growth (yoy) | -77.60% |
| Gross Profit (ttm) | -76515000 USD |
| EBITDA | -113791000 USD |
| Net Income Avi to Common (ttm) | -123776000 USD |
| Diluted EPS (ttm) | -9.4 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 146.32M USD |
| Total Cash Per Share (mrq) | 7.94 USD |
| Total Debt (mrq) | 53.27M USD |
| Total Debt/Equity (mrq) | 52.4 USD |
| Current Ratio (mrq) | 3.119 |
| Book Value Per Share (mrq) | 5.517 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -85896000 USD |
| Levered Free Cash Flow (ttm) | -44783876 USD |
Profile of Orchard Therapeutics
| Country | United States |
| State | N/A |
| City | London |
| Address | 245 Hammersmith Road |
| ZIP | W6 8PW |
| Phone | 44 20 3 808 8286 |
| Website | https://www.orchard-tx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 166 |
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Q&A For Orchard Therapeutics Stock
What is a current ORTX stock price?
Orchard Therapeutics ORTX stock price today per share is 16.7 USD.
How to purchase Orchard Therapeutics stock?
You can buy ORTX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Orchard Therapeutics?
The stock symbol or ticker of Orchard Therapeutics is ORTX.
Which industry does the Orchard Therapeutics company belong to?
The Orchard Therapeutics industry is Biotechnology.
How many shares does Orchard Therapeutics have in circulation?
The max supply of Orchard Therapeutics shares is 22.76M.
What is Orchard Therapeutics Price to Earnings Ratio (PE Ratio)?
Orchard Therapeutics PE Ratio is 0.00000000 now.
What was Orchard Therapeutics earnings per share over the trailing 12 months (TTM)?
Orchard Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Orchard Therapeutics company belong to?
The Orchard Therapeutics sector is Healthcare.
Orchard Therapeutics ORTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}